Odonate, Inc. (OTCPK: ODTC)
Health Care · Pharmaceuticals · US
$—
— today · — 1Y
Odonate, Inc. (OTCPK: ODTC) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $53.25M and employs 137 people.
trading between 123.20K and 150.00K.
Tweenvest scores Odonate, Inc. across four factors: quality 26/100. Its strongest factor is quality.
ODTC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $53.25M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- —
- Dividend yield
- —
- Beta (5Y)
- 0.42
- 52-week high
- $150,000.00
- 52-week low
- $123,200.00
- Avg volume (3M)
- —
- Shares outstanding
- 355.00
- Employees
- 137
- Next earnings
- —
About Odonate, Inc.
Odonate Therapeutics, Inc., a pharmaceutical company established in 2013 and headquartered in New York, New York, is dedicated to creating treatments for cancer. Its primary therapeutic in development is tesetaxel, an orally administered chemotherapy drug. This agent is currently undergoing a Phase III clinical study for its application in patients suffering from metastatic breast cancer.
- ISIN
- US6760794031
- Founded
- 2013
- Listed since
- Dec 7, 2017
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,244.96 | -0.83% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $272.49 | +0.83% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $150.73 | -1.19% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.03 | -0.14% |
Figures last refreshed Aug 18, 2026.